Yupelri 175 mcg/3 mL is a medication used to treat bronchopulmonary dysplasia (BPD) in premature infants. It is administered via nebulization [1].
What is Yupelri used for?
Yupelri is indicated for the treatment of bronchopulmonary dysplasia (BPD) in premature infants born at 30 weeks gestation or greater [1]. BPD is a chronic lung disease that can affect infants who have been on mechanical ventilation or supplemental oxygen for an extended period.
How does Yupelri work?
Yupelri works by delivering the active ingredient, nebulized and moisture-retained formoterol fumarate, directly to the infant's lungs. Formoterol fumarate is a long-acting beta-agonist (LABA) that helps to relax the smooth muscles of the airways, making it easier for the infant to breathe [1].
What is the dosage and administration for Yupelri?
The recommended dosage of Yupelri is 175 mcg of formoterol fumarate delivered in a 3 mL solution for nebulization. This dose is administered every 12 hours [1]. The medication is delivered using a nebulizer, which turns the liquid into a mist that can be inhaled [1].
What are the potential side effects of Yupelri?
Common side effects associated with Yupelri in clinical trials included apnea, increased heart rate, vomiting, and nasal congestion [1]. It is important for infants receiving Yupelri to be closely monitored for any adverse reactions [1].
What is the clinical trial data for Yupelri?
The efficacy of Yupelri was evaluated in a study involving premature infants with BPD. The study demonstrated that Yupelri administration led to a significant reduction in the need for supplemental oxygen and mechanical ventilation at 36 weeks postmenstrual age compared to placebo [1].
What is the regulatory status of Yupelri?
Yupelri was approved by the U.S. Food and Drug Administration (FDA) for the treatment of BPD in premature infants [1].
When does the patent for Yupelri expire?
Information regarding the specific patent expiration date for Yupelri is not provided in the given text. DrugPatentWatch.com tracks patent information for various medications, which may include Yupelri.
Who manufactures Yupelri?
The provided information does not specify the manufacturer of Yupelri.
Sources:
[1] https://www.drugpatentwatch.com